Foundation Medicine, MD Anderson Begin Second IMPACT Trial of Genomic Cancer Treatment | GenomeWeb

NEW YORK (GenomeWeb) — The University of Texas MD Anderson Cancer Center and Foundation Medicine will work together to conduct a randomized controlled trial to compare standard treatment with targeted therapies selected based on the molecular alterations in a patient's tumor.

Led by MD Anderson's Apostolia Tsimberidou, the study, IMPACT2, will evaluate whether genomically guided cancer care results in longer progression-free survival in patients with advanced disease.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: new chromatin imaging approach, and more.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.